Health Care · Biological Products, (No Diagnostic Substances)

IBRX ImmunityBio, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 132611097 filings
Russell 2000

IBRX at a glance

ImmunityBio, Inc. (IBRX, SEC CIK 1326110) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), ImmunityBio, Inc. (IBRX) reported revenue of $113.3 million (up 668.3% from FY2024) and a net loss of $351.4 million. Diluted EPS was -$0.38.
  • As of September 30, 2026, 32 institutional investment managers tracked by SignalX reported holding ImmunityBio, Inc. (IBRX) shares worth $1.3 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Simon Barry J. on October 5, 2026 of 25,000 shares at $10.75 per share.
  • In the last 90 days, IBRX insiders reported 0 open-market purchases ($0) and 2 open-market sales ($1.1M) on Form 4, a net sale of $1.1M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$113.3M
+668.3% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$1.1M
13F holders
32 funds
$1.3B · −3 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Development and commercialization of biologic drugs, with focus on regulatory approvals and post-marketing requirements
  • New emphasis on commercialization efforts for approved product ANKTIVA and building sales, marketing, and distribution capabilities
  • Strategic shift toward handling complex FDA accelerated approval pathways and orphan drug exclusivity following 2026 Orphan Drug Act codification
  • Post-marketing commitments for ANKTIVA include QUILT-3.032 trial completion by end of 2029 and annual FDA reporting up to 4 years
  • Increased focus on cybersecurity risks and use of AI in business, highlighting vulnerabilities and operational disruption potentials

Risk Factors

  • Regulatory risk from potential NCCN guideline decision on BCG-unresponsive NMIBC papillary-only disease expansion expected Q1/Q2 2026
  • Geopolitical exposure via dependency on 33 countries with ANKTIVA approval including US, UK, EU, Saudi Arabia, and MENA launches
  • Supply vulnerability as company supports FDA Expanded Access Program for rBCG to address U.S. supply constraints
  • Competitive risk from CPI combination therapies in metastatic NSCLC with conditional SFDA approval and planned commercial launch in 60 days
  • Financial risk in rapid revenue growth: ANKTIVA sales $113M FY2025, 700% YoY increase, requiring scaling of 85-person EU sales force and global partnerships

Management Discussion & Analysis

  • Revenue started from ANKTIVA sales since May 2024; no dollar amounts or YoY change disclosed
  • Operating expenses expected to increase substantially due to commercialization and R&D expansion; no margin % figures provided
  • No segment-specific performance data or best/worst performing segment disclosed
  • Cash and equivalents plus sales and potential equity offerings expected to fund operations for next 12 months; no buyback/dividend/capex details provided
  • Management highlights significant funding risks, need for additional capital to sustain operations, and regulatory/commercialization uncertainties impacting future outlook

AI summary of the IBRX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly expanded ANKTIVA indication: FDA approval on October 14, 2026 for BCG-unresponsive NMIBC with high-grade papillary-only tumors
  • Regulatory compliance: QUILT-3.032 completion and annual FDA reporting required through 2029
  • Near-term market risk: ongoing TICE BCG shortage constraining ANKTIVA uptake and clinical-trial execution
  • Liquidity risk: $334.3 million cash and securities versus $480.0 million convertible note and over $426.3 million RIPA liability
  • RIPA exposure: revenue-interest payments ranging from 5.625% to 12.50% of worldwide net sales excluding China

Management Discussion & Analysis

  • Q3 revenue $48.8M, up from $32.1M YoY, driven by ANKTIVA product revenue of $48.7M, up 53%
  • Operating loss $78.0M vs $55.6M YoY, operating margin (159.7%) vs (173.5%)
  • ANKTIVA best-performing product, revenue increased $17.0M; no segment disclosures
  • Cash, equivalents and marketable securities $334.3M vs $242.8M at December 31, 2025
  • Outlook: R&D expenses expected to increase significantly; substantial additional funding required, with going-concern doubt absent support

AI summary of the IBRX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces ImmunityBio’s business update and financial results for Q3 and nine months ended September 30, 2026
  • Financial position reported as of September 30, 2026, with detailed figures in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 net product revenue $48.7M, up 53% YoY, signaling accelerating ANKTIVA adoption and commercial traction
  • Nine-month revenue $143.6M, up 92% YoY, already exceeding full-year 2025 revenue of $113.0M
Filed Nov 9, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • ANKTIVA plus BCG met the primary endpoint in Cohort A of the randomized QUILT-2.005 trial
  • Result applies to BCG-naïve, non-muscle invasive bladder cancer patients

Item EX-99.1: Item EX-99.1

  • QUILT-2.005 met its primary efficacy endpoint in 370 BCG-naïve, high-grade NMIBC patients versus BCG alone
  • Statistically significant efficacy improvement supports potential frontline expansion beyond ANKTIVA’s current BCG-unresponsive indication
Filed Oct 14, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • FDA expanded ANKTIVA plus BCG approval to all BCG-unresponsive NMIBC, including papillary-only tumors
  • Papillary disease represents approximately 85% of the NMIBC patient population, materially broadening ANKTIVA’s addressable market

Item 7.01: Regulation FD Disclosure

  • FDA expanded ANKTIVA plus BCG approval to BCG-unresponsive NMIBC with papillary-only tumors
  • Broader eligible patient population, supporting potential commercial uptake of ANKTIVA

AI summaries of IBRX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for IBRX

Don't miss the next IBRX filing

  • Alerts as it files. A push when IBRX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut IBRX, by share count.
  • Ask anything. An AI agent that reads every IBRX filing and answers with sources.

IBRX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Simon Barry J.SellOct 5, 2026$10.75
Cohen CherylMOct 2, 2026$2.98
Cohen CherylSellOct 2, 2026$10.50
Cohen CherylMOct 2, 2026-
Cohen CherylSellJul 2, 2026$9.50
Cohen CherylMJul 2, 2026-
Cohen CherylMJul 2, 2026$2.98
Selecky ChristobelMJul 1, 2026$2.98

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$14.7M$113.3M
Operating Income--$344.2M-$256.0M
Net Income-$583.2M-$413.6M-$351.4M
Op. Margin--2334.2%-226.0%
Net Margin--2804.8%-310.2%
Balance Sheet
Total Assets$504.5M$382.9M$501.9M
Equity--$489.1M-$500.5M
ROE-84.6%70.2%
Per Share
EPS$-1.15$-0.62$-0.38
Cash Flow
Operating CF--$391.2M-$304.9M
CapEx$30.6M$6.9M$3.8M

Source: XBRL data in ImmunityBio, Inc. (IBRX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate IBRX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
IBRX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202632$1.28B
Q2 202635$1.20B
Q1 202634$855.0M
Q4 202530$202.1M
Q3 202531$195.3M
Q2 202529$192.7M
Q1 202522$110.7M
Q4 202418$79.0M
Position changes: Q2 2026 → Q3 2026
Top Sellers
New Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 231 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

IBRX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
8-KNov 9, 2026Analysis-
8-KOct 14, 2026Analysis-
4Oct 6, 2026--
4Oct 6, 2026--
8-KAug 4, 2026Analysis-
10-QAug 4, 2026Analysis
8-KJul 30, 2026Analysis-
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 1, 2026--
4Jun 26, 2026--
4Jun 10, 2026-
4Jun 10, 2026-
8-KJun 10, 2026Analysis
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 10, 2026-
4Jun 5, 2026-
8-KMay 18, 2026Analysis
8-KMay 7, 2026Analysis
10-QMay 7, 2026Analysis
8-KApr 9, 2026Analysis-

Related Health Care companies

All Health Care →

IBRX SEC filings: frequently asked questions

Are IBRX insiders buying or selling?

In the last 90 days, ImmunityBio, Inc. (IBRX) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $1.1 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold IBRX stock?

As of September 30, 2026, the largest ImmunityBio, Inc. (IBRX) holders among the 13F filers tracked by SignalX were BlackRock ($341.0 million), State Street Corp ($199.1 million), Vanguard Portfolio Management LLC ($183.0 million), Vanguard Capital Management LLC ($177.5 million), D.E. Shaw & Co ($101.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was IBRX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), ImmunityBio, Inc. (IBRX) reported revenue of $113.3 million (up 668.3% from FY2024) and a net loss of $351.4 million. Diluted EPS was -$0.38. The figures come from the XBRL data in the 10-K.

What are the main risks in IBRX's latest 10-K?

In the 10-K filed February 23, 2026, ImmunityBio, Inc. (IBRX) flagged: Regulatory risk from potential NCCN guideline decision on BCG-unresponsive NMIBC papillary-only disease expansion expected Q1/Q2 2026. Geopolitical exposure via dependency on 33 countries with ANKTIVA approval including US, UK, EU, Saudi Arabia, and MENA launches. (AI summary of the Risk Factors section.)

What did IBRX report in its latest 8-K?

ImmunityBio, Inc. (IBRX) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces ImmunityBio’s business update and financial results for Q3 and nine months ended September 30, 2026.

What are the latest IBRX SEC filings?

ImmunityBio, Inc. (IBRX) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on October 6, 2026.

What is IBRX's SEC CIK number?

ImmunityBio, Inc. (IBRX)'s SEC Central Index Key (CIK) is 1326110. EDGAR lists every IBRX filing under that number.

Ask anything about IBRX

The research agent reads IBRX's filings, financials, insider trades and 13F holders, then answers with sources.